How Fundamental Research on T cell Biology Started a Revolution in Cancer Therapy Development
DOI:
https://doi.org/10.29173/eureka28822Keywords:
immunotherapy, T cell biology, checkpoint blockade, thymus, foundational research, CAR T cell therapy, spontaneous tumour regressionAbstract
In the dynamic landscape of cancer treatment, discovery-based research in T cell biology has proven transformative, ushering in revolutionary immunotherapies. This paper navigates the impact of fundamental research on cancer therapy, tracing its evolution from 19th-century trailblazers Wilhelm Busch and Friedrich Fehleisen to recent breakthroughs by James P. Allison. By understanding T cells, the immune system's superheroes, we can illuminate the pivotal role of selectively targeting and eliminating cancer cells with unprecedented precision. Advances such as checkpoint blockade antibodies have freed tumor-infiltrating T cells from inhibition, allowing them to kill tumor cells effectively. This was a revolutionary breakthrough. Historical insights, such as the discovery of immunocompetent recirculating lymphocytes and the function of the thymus, laid the groundwork for these advances. This ongoing dialogue on resource allocation recognizes foundational research as the cornerstone for innovative therapies, ensuring a sustainable pipeline of discoveries that shape the future of T cell cancer treatment.
Downloads
References
Allison, J. P. (2018, December). Immune Checkpoint Blockade in Cancer Therapy . Nobel Lecture. San Francisco; California .
Boorman, G. A., & Everitt, J. I. (2006). Neoplastic disease. The Laboratory Rat, 479–511. https://doi.org/10.1016/b978-012074903-4/50017-0
Cleveland Clinic medical professional (Ed.). (2023, January 17). T cells: Types and function. Cleveland Clinic. https://my.clevelandclinic.org/health/body/24630-t-cells
Ferretti, J., & Köhler, W. (2016). History of Streptococcal Research. In Streptococcus pyogenes: Basic Biology to Clinical Manifestations. University of Oklahoma Health Sciences Center, Oklahoma City (OK). PMID: 26866232.
Gowans, J. L., McGREGOR, D. D., COWEN, D. M., & FORD, C. E. (1962). Initiation of immune responses by small lymphocytes. Nature, 196(4855), 651–655. https://doi.org/10.1038/196651a0
Hoyne, A. L., Wolf, A. A., & Prim, L. (1939). Fatality rates in the treatment of 998 Erysipelas patients. Journal of the American Medical Association, 113(26). https://doi.org/10.1001/jama.1939.02800510001001
Hudson, D., Fernandes, R. A., Basham, M., Ogg, G., & Koohy, H. (2023). Can we predict T cell specificity with digital biology and machine learning? Nature Reviews Immunology, 23(8), 511–521. https://doi.org/10.1038/s41577-023-00835-3
Johnson, L. A. (2021). In sickness and in health: The immunological roles of the lymphatic system. International Journal of Molecular Sciences, 22(9), 4458. https://doi.org/10.3390/ijms22094458
Kaufmann, S. H. (2019). Immunology’s coming of age. Frontiers in Immunology, 10. https://doi.org/10.3389/fimmu.2019.00684
McCarthy E. F. (2006). The toxins of William B. Coley and the treatment of bone and soft-tissue sarcomas. The Iowa orthopaedic journal, 26, 154–158.
Miller, J. F. A. P. (2004). Events that led to the discovery of t‐cell development and function – a personal recollection. Tissue Antigens, 63(6), 509–517. https://doi.org/10.1111/j.0001-2815.2004.00255.x
Miller, J. F. A. P. (2011). The Golden Anniversary of the Thymus. Nature Reviews Immunology, 11(7), 489–495. https://doi.org/10.1038/nri2993
Miller, J. F. A. P., & Sadelain, M. (2015). The journey from discoveries in fundamental immunology to cancer immunotherapy. Cancer Cell, 27(4), 439–449. https://doi.org/10.1016/j.ccell.2015.03.007
Mitra, A., Barua, A., Huang, L., Ganguly, S., Feng, Q., & He, B. (2023). From bench to bedside: The history and progress of car T cell therapy. Frontiers in Immunology, 14. https://doi.org/10.3389/fimmu.2023.1188049
Pappas, G., Kiriaze, I. J., & Falagas, M. E. (2008). Insights into infectious disease in the era of Hippocrates. International Journal of Infectious Diseases, 12(4), 347–350. https://doi.org/10.1016/j.ijid.2007.11.003
Pardoll, D. M. (2012). Immunology beats cancer: A blueprint for successful translation. Nature Immunology, 13(12), 1129–1132. https://doi.org/10.1038/ni.2392
Rasheed, A. A., & Koyyala, V. P. (2021). Chimeric antigen receptor T-cell therapy. Indian Journal of Medical and Paediatric Oncology, 42(01), 089–092. https://doi.org/10.1055/s-0041-1729437
Říhová, B., & Šťastný, M. (2015). History of immunotherapy – from Coley toxins to checkpoints of the immune reaction. Klinicka Onkologie, 28(Suppl 4). https://doi.org/10.14735/amko20154s8
Vogelzang, A., McGuire, H. M., Yu, D., Sprent, J., Mackay, C. R., & King, C. (2008). A fundamental role for interleukin-21 in the generation of T follicular helper cells. Immunity, 29(1), 127–137. https://doi.org/10.1016/j.immuni.2008.06.001
Waldman, A. D., Fritz, J. M., & Lenardo, M. J. (2020). A guide to cancer immunotherapy: From T cell basic science to clinical practice. Nature Reviews Immunology, 20(11), 651–668. https://doi.org/10.1038/s41577-020-0306-5
Wallersteiner, R. (2020). James Gowans: Immunologist whose research revealed the crucial role of lymphocytes in the immune response. BMJ, m2190. https://doi.org/10.1136/bmj.m2190
Zhang, Y., & Zhang, Z. (2020, July 1). The history and advances in cancer immunotherapy: Understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications. Nature News. https://www.nature.com/articles/s41423-020-0488-6
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Eureka
This work is licensed under a Creative Commons Attribution 4.0 International License.
By signing the Eureka publication agreement, authors agree to the following:
- The work has not been previously published in any format;
- Eureka is granted the royalty-free right to publish and disseminate the work in current and future formats;
- The work will be published in Eureka under a Creative Commons license. Eureka encourages authors to publish the work under a Creative Commons Attribution 4.0 International license (CC BY 4.0) that allows others to distribute, tweak, and build upon the work, even commercially, as long as they credit the Author(s) for the original creation.
Authors may however choose to have their work distributed under any of the Creative Commons licenses currently available by specifying their preferred license in the publication agreement. A description of the Creative Commons licenses is available here: https://creativecommons.org/licenses/
- Authors retain their copyright, including the right to subsequently publish or disseminate their work elsewhere, provided that they make reasonable efforts to ensure that the publication in Eureka is acknowledged.
- Authors agree to determine, prior to publication, whether it is necessary to obtain permissions from any third party who hold rights with respect to any photographs, illustrations, drawings, text, or any other material (“third party work”) to be published in connection with your work. Copyright permission will not be necessary if the use is determined to be fair dealing, if the work is in the public domain, or if the rights-holder has granted a Creative Commons or similar license.
- All co-authors and investigators (e.g. faculty supervisors) with claims to the intellectual property have read and signed the agreement, thereby providing their consent for the submission to be published in Eureka.
Unless otherwise specified, authors guarantee that all parts of the submission are the author’s original work. Submissions containing evidence of plagiarism will not be eligible for publication.
